ArticleiScience2026
Whole blood exchange-lymphoplasmapheresis combined transfusion as an immunotherapy in systemic lupus erythematosus.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) remains a therapeutic challenge. This study aims to evaluate the efficacy and safety of whole blood exchange-lymphoplasmapheresis combined transfusion (WLCT) in SLE. This retrospective study evaluated the clinical and immunological impact of WLCT in 84 patients with refractory SLE, compared to 61 controls receiving conventional therapy (CT). WLCT significantly attenuated disease activity, evidenced by reductions in Systemic Lupus Erythematosus Disease Activity Index scores, serum creatinine, uric acid, proteinuria, and glucocorticoid dependence. WLCT restored hemoglobin levels in autoimmune hemolytic anemia and suppressed pathogenic immunoglobulins (IgG, IgA, IgM). Flow cytometry showed expanded regulatory T cells and reduced Th17 frequencies, along with decreased IL-17A and TNF-α and increased TGF-β. Longitudinal follow-up demonstrated sustained benefits, including reduced proteinuria and neutrophil-driven inflammation at 12 months. These findings suggest that WLCT may offer therapeutic potential in controlling disease flares and mitigating organ damage in refractory SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.